← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	945	+5	+0.5%	$23.2B
2	2 Charles River Laboratories CRL $14.4B	261	+2	+0.8%	$3.28B
3	3 DELISTED bluebird bio BLUE	235	+25	+12%	$5.88B
4	4 Precigen PGEN $2.64B	173	+19	+12%	$4.63B
5	5 DELISTED SANGAMO THERAPEUTICS INC SGMO	156	-15	-9%	$561M
6	6 PTC Therapeutics PTCT $4.98B	155	-2	-1%	$1.57B
7	7 Ultragenyx Pharmaceutical RARE $1.47B	151	+25	+20%	$3.33B
8	8 DELISTED CATALENT, INC. CTLT	149	+31	+26%	$3.53B
9	ISEE 9 DELISTED IVERIC bio, Inc. Common Stock ISEE	139	+10	+8%	$1.59B
10	10 Sarepta Therapeutics SRPT $1.78B	130	+16	+14%	$811M
11	11 DELISTED Adverum Biotechnologies ADVM	96	-17	-15%	$256M
12	BLCM 12 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	81	+10	+14%	$334M
13	13 Lineage Cell Therapeutics LCTX $232M	80	+11	+16%	$113M
14	14 Atara Biotherapeutics ATRA $96M	74	+21	+40%	$696M
15	AGTC 15 DELISTED Applied Genetic Technologies Corporation AGTC	63	+4	+7%	$143M
16	16 uniQure QURE $1.45B	53	+12	+29%	$207M
17	SIOX 17 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	52	+52	–	$1.99B
18	ADAP 18 DELISTED Adaptimmune Therapeutics ADAP	45	+45	–	$384M
19	19 Abeona Therapeutics ABEO $249M	42	+30	+250%	$21.3M
20	ATHX 20 DELISTED Athersys, Inc. Common Stock ATHX	41	-12	-23%	$9.25M
21	21 DELISTED Carisma Therapeutics CARM	41	-10	-20%	$40M
22	22 Fortress Biotech FBIO $63.4M	41	-8	-16%	$28.5M
23	23 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	41	+41	–	$453M
24	24 Cellectis CLLS $113M	40	-4	-9%	$238M
25	25 Fate Therapeutics FATE $232M	39	+14	+56%	$117M